Literature DB >> 33406139

Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis.

Samuel Klistorner1, Michael H Barnett2,3, Jakob Wasserthal4, Con Yiannikas5, Joshua Barton2, John Parratt5, Yuyi You1,6, Stuart L Graham6, Alexander Klistorner1,6.   

Abstract

We describe a new single-streamline based approach to analyse diffusivity within chronic MS lesions. We used the proposed method to examine diffusivity profiles in 30 patients with relapsing multiple sclerosis and observed a significant increase of both RD and AD within the lesion core (0.38+/-0.09 μm2/ms and 0.30+/-0.12 μm2/ms respectively, p<0.0001 for both) that gradually and symmetrically diminished away from the lesion. T1-hypointensity derived axonal loss correlated highly with ΔAD (r = 0.82, p<0.0001), but moderately with ΔRD (r = 0.60, p<0.0001). Furthermore, the trendline of the ΔAD vs axonal loss intersected both axes at zero indicating close agreement between two measures in assessing the degree of axonal loss. Conversely, the trendline of the ΔRD function demonstrated a high positive value at the zero level of axonal loss, suggesting that even lesions with preserved axonal content exhibit a significant increase of RD. There was also a significant negative correlation between the level of preferential RD increase (ΔRD-ΔAD) in the lesion core and the degree of axonal damage (r = -0.62, p<0.001), indicating that ΔRD dominates in cases with milder axonal loss. Modelling diffusivity changes in the core of chronic MS lesions based on the direct proportionality of ΔAD with axonal loss and the proposed dual nature of ΔRD yielded results that were strikingly similar to the experimental data. Evaluation of lesions in a sizable cohort of MS patients using the proposed method supports the use of ΔAD as a marker of axonal loss; and the notion that demyelination and axonal loss independently contribute to the increase of RD in chronic MS lesions. The work highlights the importance of selecting appropriate patient cohorts for clinical trials of pro-remyelinating and neuroprotective therapeutics.

Entities:  

Year:  2021        PMID: 33406139      PMCID: PMC7787472          DOI: 10.1371/journal.pone.0244766

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  26 in total

1.  Investigating the prevalence of complex fiber configurations in white matter tissue with diffusion magnetic resonance imaging.

Authors:  Ben Jeurissen; Alexander Leemans; Jacques-Donald Tournier; Derek K Jones; Jan Sijbers
Journal:  Hum Brain Mapp       Date:  2012-05-19       Impact factor: 5.038

2.  TractSeg - Fast and accurate white matter tract segmentation.

Authors:  Jakob Wasserthal; Peter Neher; Klaus H Maier-Hein
Journal:  Neuroimage       Date:  2018-08-04       Impact factor: 6.556

3.  Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords.

Authors:  Eric C Klawiter; Robert E Schmidt; Kathryn Trinkaus; Hsiao-Fang Liang; Matthew D Budde; Robert T Naismith; Sheng-Kwei Song; Anne H Cross; Tammie L Benzinger
Journal:  Neuroimage       Date:  2011-01-13       Impact factor: 6.556

4.  The contribution of gliosis to diffusion tensor anisotropy and tractography following traumatic brain injury: validation in the rat using Fourier analysis of stained tissue sections.

Authors:  Matthew D Budde; Lindsay Janes; Eric Gold; Lisa Christine Turtzo; Joseph A Frank
Journal:  Brain       Date:  2011-07-15       Impact factor: 13.501

5.  Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability.

Authors:  Daniel S Reich; Seth A Smith; Eliza M Gordon-Lipkin; Arzu Ozturk; Brian S Caffo; Laura J Balcer; Peter A Calabresi
Journal:  Arch Neurol       Date:  2009-08

6.  Fractional anisotropy changes in Alzheimer's disease depend on the underlying fiber tract architecture: a multiparametric DTI study using joint independent component analysis.

Authors:  Stefan J Teipel; Michel J Grothe; Massimo Filippi; Andreas Fellgiebel; Martin Dyrba; Giovanni B Frisoni; Thomas Meindl; Arun L W Bokde; Harald Hampel; Stefan Klöppel; Karlheinz Hauenstein
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.

Authors:  Ari J Green; Jeffrey M Gelfand; Bruce A Cree; Carolyn Bevan; W John Boscardin; Feng Mei; Justin Inman; Sam Arnow; Michael Devereux; Aya Abounasr; Hiroko Nobuta; Alyssa Zhu; Matt Friessen; Roy Gerona; Hans Christian von Büdingen; Roland G Henry; Stephen L Hauser; Jonah R Chan
Journal:  Lancet       Date:  2017-10-10       Impact factor: 79.321

8.  Tract profiles of white matter properties: automating fiber-tract quantification.

Authors:  Jason D Yeatman; Robert F Dougherty; Nathaniel J Myall; Brian A Wandell; Heidi M Feldman
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations.

Authors:  P A Brex; G J Parker; S M Leary; P D Molyneux; G J Barker; C A Davie; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

View more
  2 in total

Review 1.  Remyelination Trials: Are We Expecting the Unexpected?

Authors:  Alexandr Klistorner; Michael Barnett
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-10

2.  Advanced diffusion MRI and image texture analysis detect widespread brain structural differences between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  Olayinka Oladosu; Wei-Qiao Liu; Lenora Brown; Bruce G Pike; Luanne M Metz; Yunyan Zhang
Journal:  Front Hum Neurosci       Date:  2022-08-12       Impact factor: 3.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.